Risk for pancreatitis was not elevated among users of tirzepatide relative to placebo, despite the presence of elevated pancreatic enzymes.

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.

For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist ...

A study has found no evidence that glucagon-like peptide 1 receptor agonist (GLP1-RA) use is associated with an increased ...

One in eight people living in the United States has taken a GLP-1 medication — such as Ozempic, Mounjaro, or Zepbound — for ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

As GLP-1 RA use soars, experts are worried that patients may not be getting the right nutrients in their diets. How can ...

Glucagon-like peptide-1 (GLP-1) is a peptide hormone which role extends beyond well-known carbohydrates metabolism. In in vitro studies GLP-1 receptor agonism is associated with regulation of several ...

By enhancing insulin secretion, inhibiting glucagon release ... benefits in patients with MASLD and metabolic comorbidities like type 2 diabetes. In the LEAN trial, liraglutide 1.8 mg daily ...